Premium
Resolution of acyclovir‐associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature
Author(s) -
Watson W. A.,
Rhodes N. J.,
Echenique I. A.,
Angarone M. P.,
Scheetz M. H.
Publication year - 2017
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12520
Subject(s) - medicine , neurotoxicity , renal function , bayesian probability , vancomycin , creatinine , population , clearance , therapeutic drug monitoring , surgery , anesthesia , urology , pharmacokinetics , toxicity , statistics , mathematics , environmental health , biology , bacteria , genetics , staphylococcus aureus
Summary What is known and objective Neurotoxicity is a side effect of acyclovir. We report the first case, to our knowledge, whereby Bayesian‐informed clearance estimates supported a therapeutic intervention for acyclovir‐associated neurotoxicity. Case summary A 62‐year‐old male with the diagnosis of disseminated zoster was being treated with intravenous ( IV ) acyclovir when he developed symptoms of acute neurotoxicity. Acyclovir had been dose‐adjusted for renal dysfunction according to traditional creatinine clearance estimates; however, as the patient was also on vancomycin, Bayesian estimates of vancomycin clearances were performed, which revealed a 2‐fold lower creatinine clearance. In response to the Bayesian estimates, acyclovir was discontinued, and improvements in mentation were noted within 24 hours. What is new and conclusion Alternate approaches to estimate renal function beyond Cockcroft‐Gault, such as a Bayesian approach used in our patient, should be considered when population estimates are likely to be inaccurate and potentially dangerous to the patient.